7 Best Peptides for Epilepsy and Seizures

What to Know Before Choosing a Peptide for Epilepsy and Seizures

The honest starting point for this topic is that peptide research for epilepsy is entirely preclinical as of 2026. Every compound in this guide earned its place because researchers, biohackers, or medical scientists are actively studying or discussing it for seizure-related mechanisms, not because any of them has been tested in a human clinical trial for epilepsy and found to work. That distinction matters enormously here, and it shapes how every entry below is written.

A peptide earns a slot in this guide if people are researching it, publishing on it, or actively discussing it in the context of epilepsy and seizures. That standard includes compounds at every regulatory tier: FDA-approved substances, telemedicine-accessible compounds, and research-only chemicals alike. No compound is excluded because its evidence is thin or because it sits outside the approval system. Where evidence is thin, the entry says so plainly.

The entries below are numbered by how prominently each compound appears in the published research and in documented discussion for this goal. That order is not a ranking of one compound as better than another for any individual. Several of these compounds address completely different mechanisms of seizure activity, so framing them as a hierarchy would mislead rather than inform. The numbers give the list a spine; they do not tell you which peptide to choose.

One important framing point before reading on: epilepsy is a serious neurological condition. No experimental peptide should be considered a substitute for physician-prescribed antiseizure medications. The research summarized here is genuine and the mechanisms are plausible, but the safety and efficacy picture in actual humans is simply unknown for all of these compounds. Read this guide as a map of what researchers are exploring, not as a protocol.

1. Neuropeptide Y: The Brain's Own Circuit Breaker

Neuropeptide Y, abbreviated NPY, is a 36-amino-acid peptide produced naturally in the brain and is the most scientifically credible entry in this entire field. Unlike every other compound discussed here, NPY has been tested on actual human brain tissue, giving it a level of human-adjacent evidence that no other peptide in this space has reached.

Researchers at Lund University conducted studies using brain tissue samples taken from patients with drug-resistant epilepsy, a population for whom conventional medications have already failed. When NPY was applied to this tissue, it reduced seizure-like electrical activity. The researchers described the finding as an important step forward while being careful to note that tissue experiments are not the same as clinical trials in living patients. No live human trial has been completed, and NPY itself is not a commercially available drug candidate, but this is the closest any peptide in this space has come to human-relevant evidence.

The mechanism is well characterized. During a seizure, NPY is naturally released in the affected brain regions, acting as one of the brain's built-in dampening signals. It binds to three receptor subtypes labeled Y1, Y2, and Y5, and through those receptors it enhances inhibitory GABA-mediated circuits while simultaneously reducing the release of glutamate, the brain's primary excitatory neurotransmitter. Think of it as a biological dimmer switch that activates automatically when electrical activity in the brain climbs too high.

There is an indirect clinical connection worth noting. Valproic acid, one of the most widely prescribed antiseizure medications, is known to increase NPY levels in the hippocampus and thalamus by roughly 50 percent. This does not prove that direct NPY supplementation would work in humans, but it suggests that boosting NPY signaling is a strategy that already underlies an approved treatment, lending the research a degree of biological plausibility that purely experimental compounds lack.

NPY is not available as a standalone research chemical in the way that Semax or Selank are. Its relevance here is primarily scientific: it defines a target, illuminates a mechanism, and represents the strongest preclinical case for why neuropeptides might eventually play a role in epilepsy management. The practical route to influencing NPY signaling in humans remains an open research question as of 2026.

2. Selank: The Most Mechanistically Specific Research Peptide

Selank is a synthetic heptapeptide developed in Russia at the Institute of Molecular Genetics, originally studied as an anxiolytic and nootropic agent. In the context of epilepsy research, it has attracted attention because its anticonvulsant mechanism is unusually direct: it appears to work specifically on the GABAergic system, the same inhibitory signaling network targeted by benzodiazepines and most classic antiseizure medications.

The evidence for Selank in this area is preclinical. It has been tested in the pentylenetetrazole kindling model, a widely used animal setup that mimics chronic epilepsy by progressively sensitizing the brain to seizures over time. It showed anticonvulsant activity in that model. It has also been studied in the kainic acid acute status epilepticus model, a separate preclinical approach that mimics severe, prolonged seizure activity. And in a third set of experiments, researchers found that Selank can block flumazenil-induced seizures. Flumazenil is a drug that reverses benzodiazepine sedation and, in doing so, can trigger severe rebound seizures in people who have become dependent. That Selank interferes with this process is considered strong indirect confirmation of its GABAergic mechanism.

The specific actions identified in animal research include positive allosteric modulation of GABA-A receptors, meaning Selank appears to enhance the function of these inhibitory receptors without directly activating them in the way a benzodiazepine does. It also appears to upregulate GAD67, the enzyme responsible for synthesizing GABA in neurons, which in theory would increase the amount of inhibitory neurotransmitter available in the brain.

No human clinical trial data has been published for Selank in epilepsy or seizures as of 2026. What exists is the preclinical profile described above, along with its established use in Russian and Eastern European clinical settings as an anxiolytic agent, where it is generally described as well-tolerated at standard doses. Research communities in the biohacking and nootropic space discuss Selank for its neurological effects, and it is available as a research chemical, primarily in nasal spray form. Anyone using it outside a clinical research context is doing so without an established safety or efficacy profile for seizure-related purposes.

3. Semax: Neuroprotection After Seizure Activity

Semax is a synthetic analog of a fragment of the stress hormone ACTH, developed in Russia and studied extensively as a neuroprotective and cognitive-enhancing agent. Its interest in the epilepsy space differs from Selank's in an important way. Where Selank's animal evidence points toward direct seizure suppression, Semax's evidence points more toward protecting the brain from the damage that seizures cause and toward reducing the likelihood of recurrent seizures after an initial severe episode.

The animal model evidence involves two preclinical setups. In the kainic acid status epilepticus model, Semax showed post-ictal neuroprotection, meaning it appeared to reduce neuronal damage after a severe seizure was induced. In the lithium-pilocarpine model, a different approach to inducing prolonged seizure activity, Semax was associated with a reduction in spontaneous recurrent seizures, the kind of ongoing, unprovoked seizure activity that defines epilepsy rather than a single isolated event.

The mechanism researchers point to involves activation of the BDNF-TrkB-PI3K-Akt signaling pathway. BDNF stands for brain-derived neurotrophic factor, a protein that supports the survival and growth of neurons. TrkB is the receptor through which BDNF acts, and PI3K-Akt is the downstream intracellular chain it activates. Stimulating this pathway promotes neuronal survival and appears to reduce a process called mossy fiber sprouting, a pathological reorganization of hippocampal circuitry that develops after status epilepticus and is associated with recurrent spontaneous seizures emerging over time.

Like Selank, Semax has no published human clinical trial data for epilepsy. Its general tolerability profile in the nootropic and research community is considered relatively benign. It is available as a research chemical, typically in nasal spray or injectable forms. The epilepsy-specific discussion in research circles situates Semax more as a neuroprotective adjunct than as a primary anticonvulsant, a meaningful distinction when thinking about where it fits in the experimental landscape.

4. Occidentalin-1202: The Most Potent Preclinical Finding

Occidentalin-1202 is a peptide isolated from the venom of the Polybia occidentalis wasp. It is not available for human use, has not entered any clinical trial, and sits firmly in early-stage experimental research. It appears here because the preclinical efficacy data is striking enough that it has generated real attention in the peptide research community.

In rodent models, occidentalin-1202 produced complete seizure protection at very small doses in both kainic acid and pentylenetetrazole models, two standard preclinical benchmarks for anticonvulsant research. It was also active in a chronic temporal lobe epilepsy model induced by pilocarpine, which is relevant because temporal lobe epilepsy is the most common form of focal epilepsy in adults, and many patients with this type are drug-resistant. The compound also crosses the blood-brain barrier in rodents, a property that eliminates one of the major obstacles keeping most peptides from reaching their central nervous system targets.

The mechanism is specific: occidentalin-1202 blocks kainate receptors, which are ionotropic glutamate receptors that, when overactivated, drive sustained and damaging excitatory activity in the brain. That kind of excitatory overdrive is precisely what is associated with status epilepticus and temporal lobe seizures. Blocking kainate receptors is a pharmacologically validated strategy; approved drugs targeting related excitatory pathways already exist in clinical practice.

The published research on occidentalin-1202 appeared in Brain Communications, an Oxford Academic journal, lending it more scientific credibility than a typical preprint or vendor-commissioned analysis. Even so, the researchers were clear that no work on dosing, safety, or human translation has been done. This is a compound to follow in the research literature, not one to seek out for personal use.

5. BPC-157: Targeting the Blood-Brain Barrier After Seizures

BPC-157 is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It is one of the more widely used research peptides across multiple domains, known primarily for its cytoprotective and tissue-healing properties. Its relevance to epilepsy research addresses a different aspect of the problem than most compounds above: rather than trying to prevent seizures from starting, its studied action relates to repairing damage that seizures cause to the blood-brain barrier.

The blood-brain barrier is the tightly regulated interface between the bloodstream and the central nervous system. During and after severe seizures, this barrier breaks down, and that breakdown creates a destructive feedback loop. When the barrier is compromised, inflammatory molecules that would normally be excluded from the brain flood in, worsening neuroinflammation and increasing the likelihood of further seizures. Restoring barrier integrity is therefore a legitimate therapeutic target independent of seizure initiation itself.

In kainic acid status epilepticus animal models, BPC-157 has been shown to reduce leakage through the blood-brain barrier, as measured by Evans Blue dye exclusion testing, and to restore levels of two tight junction proteins, ZO-1 and claudin-5, that are critical to barrier function. Tight junction proteins act as the molecular seals between the endothelial cells lining the brain's blood vessels. When they are depleted during seizure activity, the barrier becomes permeable. BPC-157 appears to promote their restoration in the animal model context.

No human clinical trial data has been published for BPC-157 in epilepsy. Community use of BPC-157 is widespread for other purposes, primarily musculoskeletal and gastrointestinal healing, and it is available as a research chemical. Its relevance to the epilepsy discussion is primarily in the research literature rather than in active community protocols focused specifically on seizure control.

6. A1R-CT: Amplifying Adenosine's Natural Anticonvulsant Signal

A1R-CT is a research peptide that takes a notably different approach from the others on this list. Rather than introducing a foreign mechanism, it is designed to amplify one of the brain's own natural anticonvulsant systems: adenosine signaling through the adenosine A1 receptor.

Adenosine is a neuromodulator that the brain releases naturally during and after periods of intense neural activity, including seizures. Its binding to A1 receptors has an inhibitory effect on neuronal firing, which is one reason the brain uses it as part of its own seizure-termination machinery. However, a scaffolding protein called neurabin normally limits how strongly A1 receptors can signal. A1R-CT is a blocking peptide that disrupts the interaction between neurabin and the A1 receptor, effectively removing the governor from the system and allowing adenosine to exert a stronger anticonvulsant effect.

In mouse models of recurring seizures, nasal delivery of A1R-CT reduced the frequency of recurring seizure episodes. The nasal delivery route is significant because it suggests the peptide can reach brain targets without intravenous administration, and the recurring seizure model is directly relevant to epilepsy as a chronic condition rather than to isolated acute events. The research is associated with peer-reviewed publications and work from Hebrew University, and it has been covered by epilepsy advocacy organizations as a promising preclinical direction.

A1R-CT remains an experimental compound with no human trial data and no availability for clinical use. No research chemical market has developed around it in the way that Semax or Selank are available. Its presence here reflects the quality and relevance of the underlying science rather than any real-world uptake.

7. TXM-CB3: A 2026 Entry Targeting Drug-Resistant Epilepsy

TXM-CB3 is a thioredoxin-mimetic tripeptide and one of the newest experimental compounds in this space, with key research emerging in early 2026. It earns a place on this list specifically because it was developed with drug-resistant epilepsy as its explicit target, addressing the roughly 30 percent of epilepsy patients for whom existing medications fail to provide adequate control.

The 2026 preclinical studies showed TXM-CB3 reduced seizure frequency, delayed seizure onset, and preserved neuronal integrity in the hippocampus across experimental models of drug-resistant epilepsy. Hippocampal neurons are among the most vulnerable to seizure-related damage, and their loss is associated with memory impairment and worsening seizure patterns over time. The researchers attributed these effects to the compound's dual action on oxidative stress and neuroinflammation. Oxidative stress refers to the accumulation of reactive oxygen species, highly reactive molecules generated in large quantities during seizure activity that damage neurons. Neuroinflammation refers to the sustained immune activation in the brain that both results from seizures and, in a feedback loop, makes subsequent seizures more likely. Targeting both processes simultaneously is what made the 2026 findings noteworthy within the experimental epilepsy research community.

The researchers who published this work were explicit that the findings come from experimental models and that further studies on safety, dosing, and human efficacy are needed before any clinical translation is warranted. TXM-CB3 is not available as a research chemical in the way that better-known peptides are, and there is no community use to point to. Its presence here reflects genuine scientific interest from a peer-reviewed 2026 publication rather than real-world uptake. This is a compound worth tracking as the research matures.

How These Peptides Compare

Frequently Asked Questions

Are any peptides approved for treating epilepsy?

No peptide has received FDA approval for epilepsy or seizure control as of 2026. All of the compounds discussed in this guide are either research chemicals or purely experimental compounds that have not entered human clinical trials for this indication. Approved seizure medications include small molecules and benzodiazepines such as levetiracetam, lamotrigine, valproic acid, and diazepam nasal spray, none of which are peptides.

Is it safe to use research peptides alongside prescribed seizure medications?

This is a question for a neurologist, not a general information guide, because the interaction between any experimental compound and a specific antiseizure medication regimen is unknown. There is at least one community report of new-onset seizure activity occurring in someone using injectable research peptides, suggesting that unregulated peptide use may lower seizure thresholds in some individuals rather than raise them. Anyone with epilepsy should discuss any supplement or experimental compound with their neurologist before use, and no experimental peptide should be used as a substitute for prescribed medication.

Why is there so little human evidence for peptides in epilepsy?

Crossing the blood-brain barrier is genuinely difficult for most peptides, and designing human trials for seizure disorders involves significant safety and ethical complexity. Most of the peptides in this guide are also not owned by pharmaceutical companies with the resources to fund large-scale human trials, which means preclinical findings tend to stay preclinical for longer than they might with commercial development backing. The scientific interest is real, but the gap between animal model results and human clinical evidence is wider in this field than in many others.

Which peptide has the most human-relevant evidence for epilepsy?

Neuropeptide Y has the most human-adjacent evidence, having been tested directly on brain tissue taken from patients with drug-resistant epilepsy, where it reduced seizure-like electrical activity. This is still not the same as a completed clinical trial in living patients, but it is a meaningful step beyond rodent models. Researchers at Lund University who conducted this work described it as an important advance while being clear that clinical application remains a future goal rather than a current reality.

Can people with epilepsy use Semax or Selank for general nootropic benefits?

This is a question for a qualified neurologist rather than a general information resource, because the answer depends entirely on individual factors including current medications, seizure type, and overall health history. What the animal research shows is that Selank has demonstrated anticonvulsant activity through GABAergic mechanisms and Semax has shown neuroprotective effects in seizure models, so the pharmacology is not obviously contraindicated. However, no human safety data exists for either compound in the epilepsy population, and interactions with existing antiseizure medications are entirely unknown.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for epilepsy and seizures in one place.